VolitionRx Q2 2026 revenue was USD 0.4 million, roughly flat versus the year-earlier quarter.
Operating loss narrowed 34% to USD 4.2 million; operating expenses fell 32% on a cost-reduction program.
Net cash used in operating activities decreased 18% to USD 5.2 million.
First-half 2026 revenue more than doubled to USD 1.4 million, up 112% from the prior-year period.
Management cited talks with over a dozen diagnostics groups on licensing; highlighted the Sysmex collaboration and a potential USD 5 million feline milestone.
VNRX•
